Price target
3,115.85RINR+421.25+15.63%
The 12 analysts offering 1 year price forecasts for AJANTA PHARMA LTD have a max estimate of 3,750.00 and a min estimate of 2,288.00.
Analyst rating
Based on 12 analysts giving stock ratings to AJANTA PHARMA LTD in the past 3 months.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong buy
8
Buy
1
Hold
1
Sell
1
Strong sell
1
EPS
Forecast
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
0.00
5.00
10.00
15.00
20.00
Reported
Estimate
Currency: INR
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Reported
16.50
15.50
16.60
16.09
19.53
17.26
18.59
—
—
Estimate
12.97
15.90
15.33
13.27
17.25
18.00
17.50
19.70
—
Surprise
+27.25%
−2.52%
+8.26%
+21.28%
+13.22%
−4.11%
+6.23%
—
—
Revenue
Forecast
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
0.00
3.50 B
7.00 B
10.50 B
14.00 B
Reported
Estimate
Currency: INR
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Reported
10.21 B
10.28 B
11.05 B
10.54 B
11.71 B
12.06 B
11.77 B
—
—
Estimate
9.97 B
10.49 B
10.53 B
10.32 B
11.30 B
11.45 B
11.69 B
11.40 B
—
Surprise
+2.41%
−1.95%
+4.98%
+2.11%
+3.70%
+5.38%
+0.66%
—
—
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
Frequently Asked Questions
AJANTPHARM EPS for the last quarter is 18.59 INR despite the estimation of 17.50 INR. In the next quarter EPS is expected to reach 19.70 INR. Track more of AJANTA PHARMA LTD financials and stay on top of what is up with the company.
In the next quarter AJANTA PHARMA LTD revenue is expected to reach 11.40 B INR. Check out AJANTA PHARMA LTD revenue and earnings and make informed decisions.
According to analysts, AJANTPHARM price target is 3,115.83 INR with a max estimate of 3,750.00 INR and a min estimate of 2,288.00 INR. Check if this forecast comes true in a year, meanwhile watch AJANTA PHARMA LTD stock price chart and keep track of the current situation with AJANTPHARM news and stock market news.
We've gathered opinions of 12 analysts rating AJANTPHARM stock in the past 3 months. Most of them backed up the strong buy trend, and after taking into account other opinions, the overall rating was calculated as buy. Note that it's not a trading advice — your own analysis is still required.